

## 24<sup>th</sup> Infectious Diseases Working Party Educational Course

Wednesday, 24<sup>th</sup> November 2021

<b>14:00 - 14:05</b>	<b>Welcome</b>	Dina Averbuch Rafael de la Cámara
<b>14:05 - 15:40</b>	<b>Session I: Spotlight on Fungal infections</b> <b>Chairs:</b> Johan Maertens and Monica Slavin	
	Diagnosis, antimicrobial susceptibility and treatment of invasive candidiasis	Patricia Muñoz
	Diagnosis, antimicrobial susceptibility and treatment of Aspergillosis	Rafael de la Cámara
	Diagnosis and treatment of Mucormycosis	Livio Pagano
	Epidemiology, diagnosis and treatment of rare fungal infections (Fusarium, Cryptococcus, black fungi, etc.)	Dionysios Neofytos
	Q&A	
<b>15:40 - 15:50</b>	<b>Break</b>	
<b>15:50 - 17:25</b>	<b>Session II: Prophylaxis of infections following HSCT</b> <b>Chairs:</b> Dina Averbuch and Malgorzata Mikulska	
	Prophylaxis of fungal infections	Catherine Cordonnier Ronen Ben Ami
	Breakthrough fungal infections on antifungal prophylaxis: epidemiology, diagnosis and treatment	
	How letermovir prophylaxis changed the management of CMV	Per Ljungman
	Fluoroquinolone prophylaxis: friend or foe?	Dafna Yahav
	Q&A	
<b>17:25 - 17:40</b>	<b>Break</b>	
<b>17:40 - 18:40</b>	<b>Industry Symposium kindly sponsored by Atara Bio</b> <b>EBV+PTLD post HCT – A rare and potentially fatal post transplant complication</b> <b>Chair: Rafael de la Cámara</b>	
	Treatment options for patients with EBV+PTLD post HCT who failed first line therapy	Jan Styczynski
	Investigational off-the-shelf allogeneic EBV+ T cells	Patrizia Comoli

## 24<sup>th</sup> Infectious Diseases Working Party Educational Course

Thursday, 25<sup>th</sup> November 2021

<b>14:00 - 14:45</b>	<p><b>Industry Symposium kindly sponsored by Moderna</b>  <b>Chair: Rafael de la Cámara</b>          From COVID-19 vaccines to broader therapeutics based on mRNA-encoded proteins</p>	César Sanz
<b>14:45 - 15:00</b>	<b>Break</b>	
<b>15:00 - 16:15</b>	<p><b>Session III: Diagnosis and treatment of infections</b>  <b>Chairs: Jan Styczynski and Andreas Groll</b></p> <p>Advances in the microbiological diagnosis of infections: next generation sequencing, etc.</p> <p>How to use new antimicrobials for resistant Gram-negatives in HSCT patients</p> <p>Contribution of clinical pharmacologist to the management of HSCT infections</p> <p>"The child is not a small adult". Specific aspects of infections management in children following HSCT</p> <p>Q&amp;A</p>	<p>Jacob Moran Gilad</p> <p>Dina Averbuch</p> <p>Pier Giorgio Cojutti</p> <p>Elio Castagnola</p>
<b>16:15 - 16:30</b>	<b>Break</b>	
<b>16:30 - 17:45</b>	<p><b>Session IV: Infections in specific patients' populations</b>  <b>Chairs: Rafael de la Cámara and Lidia Gil</b></p> <p>Infections in HSCT patients hospitalized in the ICU</p> <p>Infections following CAR T therapy</p> <p>Infections during GVHD: epidemiology, surveillance and treatment</p> <p>Infections following autologous HSCT</p> <p>Q&amp;A</p>	<p>Peter Schellongowski</p> <p>Lidia Gil</p> <p>Olaf Penack</p> <p>Georg Maschmeyer</p>
<b>17:45 - 18:00</b>	<b>Break</b>	
<b>18:00 - 19:00</b>	<p><b>Session V: Predisposition to infections following HSCT</b>  <b>Chairs: Roy Chemaly and Franco Locatelli</b></p> <p>Immune reconstitution and infection risk following HSCT</p> <p>Management of HSCT patients with pre-transplant colonizations or infections</p> <p>Microbiome, predisposition to infections and fecal transplantation</p> <p>Q&amp;A</p>	<p>Daniel Teschner</p> <p>Murat Akova</p> <p>Ilan Youngster</p>

**24<sup>th</sup> Infectious Diseases Working Party Educational Course**Friday, 26<sup>th</sup> November 2021**14:00 - 15:00****Session VI: The classic and the new****Chairs:** Per Ljungman and Joshua A. Hill

Management of Adenovirus

Simone Cesaro

Challenging viral infections: HHV6, JC virus, etc.

Jan Styczynski

Management of HSV and VZV. The new subunit VZ vaccine.

Dan Engelhard

Q&amp;A

**15:00 - 15:15****Break****15:15 - 16:40****Session VII: COVID-19****Chairs:** Galia Rahav and Simone Cesaro

COVID: update in HSCT and CAR T patients and vaccinations

Per Ljungman

Treatment of COVID-19 in HSCT/CART-T and oncohematologic patients

Malgorzata Mikulska

Monoclonals for prevention and treatment of COVID-19

Sylvain Meylan

Q&amp;A

**16:40 - 16:45****Closing**

Dina Averbuch

Rafael de la Cámara

**16:45 - 17:15****Break****17:15 - 20:15****Scientific Business Meeting**

Open to all